Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
作者: Kathleen M. MahoneySusanna JacobusRupal S. BhattJiaxi SongIngrid CarvoSu-Chun ChengMekailah SimpsonAndré P. FayIgor PuzanovM. Dror MichaelsonMichael B. AtkinsDavid F. McDermottSabina SignorettiToni K. Choueiri
作者单位: 1Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3Department of Statistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
4Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA
5Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
6PUCRS School of Medicine, Porto Alegre, Brazil
7Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
8Department of Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC
刊名: Clinical Genitourinary Cancer, 2016, Vol.14 (4), pp.304-313.e6
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2016.02.007
关键词: BevacizumabRenal cell carcinomaTemsirolimusTKI-refractory disease
原始语种摘要: Abstract(#br)Background(#br)Inhibiting VEGF and mammalian target of rapamycin (mTOR) pathways are standard treatment approaches for patients with metastatic renal cell carcinoma (mRCC). Here we report the activity and safety of the VEGF ligand inhibitor bevacizumab and the mTOR inhibitor temsirolimus combination in patients with clear cell (CC) and non-clear cell (NCC) mRCC whose disease had failed to respond to prior VEGF blockade.(#br)Patients and Methods(#br)In this phase 2 investigator-initiated multicenter study, patients received bevacizumab and temsirolimus. The primary end point was 4-month progression-free survival (PFS) rate. Secondary end points included overall response rate, median overall survival (OS), toxicity, and correlative studies of biomarkers downstream of...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:1.429 (2012)

×